NASDAQ:CELZ Creative Medical Technology (CELZ) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free CELZ Stock Alerts $4.31 -0.09 (-2.05%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$4.31▼$4.3150-Day Range$4.30▼$5.7352-Week Range$3.93▼$10.28Volume2,773 shsAverage Volume131,656 shsMarket Capitalization$5.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Creative Medical Technology alerts: Email Address Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About Creative Medical Technology Stock (NASDAQ:CELZ)Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Read More CELZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELZ Stock News HeadlinesMay 16, 2024 | americanbankingnews.comBrokers Offer Predictions for Creative Medical Technology Holdings, Inc.'s Q2 2024 Earnings (NASDAQ:CELZ)May 15, 2024 | americanbankingnews.comFY2026 Earnings Estimate for Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Issued By Roth CapitalApril 24, 2024 | morningstar.comCreative Medical Technology Holdings Inc CELZMarch 24, 2024 | finance.yahoo.comCreative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 18, 2024 | forbes.comMedical Practices And Branding In A Digital AgeMarch 18, 2024 | theglobeandmail.comCreative Medical Technology Skyrockets on Word of New Diabetes MedicationMarch 7, 2024 | msn.comWhy Is Diabetes Focused Creative Medical Stock Surging On Thursday?March 7, 2024 | markets.businessinsider.comCreative Medical Announces FDA Authorization For Expanded Access For CELZ-201; Stock UpMarch 7, 2024 | marketwatch.comCreative Medical Shares Rise 37% After FDA Authorization for CELZ-201March 7, 2024 | msn.comCreative Medical stock rallies for second day on FDA updatesMarch 7, 2024 | finance.yahoo.comCreative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded AccessMarch 6, 2024 | morningstar.comCreative Medical Technology Holdings IncMarch 6, 2024 | markets.businessinsider.comCreative Medical Receives FDA Orphan Drug Designation For CELZ-101; Stock Up In Pre-marketMarch 6, 2024 | marketwatch.comCreative Medical Shares Rally Premarket on FDA Orphan DesignationMarch 6, 2024 | msn.comCreative Medical stock rallies 18% on FDA orphan drug designationMarch 6, 2024 | businesswire.comCreative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation TherapyFebruary 15, 2024 | investing.comCreative Medical Technology Holdings Inc (CELZ)February 9, 2024 | benzinga.comSteven L White's Net WorthDecember 20, 2023 | finance.yahoo.comCreative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back PainOctober 11, 2023 | msn.comCreative Medical to initiate trial of lower back pain treatmentOctober 10, 2023 | markets.businessinsider.comCreative Medical Gets IRB Approval For StemSpine Trial Using AlloStem Cell TherapyOctober 10, 2023 | finance.yahoo.comCreative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back PainSeptember 22, 2023 | finance.yahoo.comWhat Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy StockSeptember 19, 2023 | finance.yahoo.comCreative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back PainAugust 24, 2023 | finance.yahoo.comWhat Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?See More Headlines Receive CELZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Creative Medical Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today5/24/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CELZ CUSIPN/A CIK1187953 Webwww.creativemedicaltechnology.com Phone(833) 336-7636FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,290,000.00 Net MarginsN/A Pretax Margin-58,633.34% Return on Equity-46.50% Return on Assets-44.93% Debt Debt-to-Equity RatioN/A Current Ratio23.54 Quick Ratio23.53 Sales & Book Value Annual Sales$10,000.00 Price / Sales581.85 Cash FlowN/A Price / Cash FlowN/A Book Value$6.85 per share Price / Book0.63Miscellaneous Outstanding Shares1,350,000Free Float1,304,000Market Cap$5.82 million OptionableNot Optionable Beta2.22 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Timothy Warbington (Age 62)Co-Founder, Chairman, President & CEO Comp: $429kMr. Donald Dickerson (Age 59)Senior VP, CFO & Director Comp: $390kKey CompetitorsPalisade BioNASDAQ:PALINanoString TechnologiesNASDAQ:NSTGQTitan PharmaceuticalsNASDAQ:TTNPFresh Tracks TherapeuticsNASDAQ:FRTXKiromic BioPharmaNASDAQ:KRBPView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 16,374 shares on 5/20/2024Ownership: 1.213%Aaron Wealth Advisors LLCBought 16,400 shares on 4/25/2024Ownership: 1.206%Timothy WarbingtonBought 800 shares on 6/27/2023Total: $3,552.00 ($4.44/share)View All Insider TransactionsView All Institutional Transactions CELZ Stock Analysis - Frequently Asked Questions How have CELZ shares performed in 2024? Creative Medical Technology's stock was trading at $4.61 at the beginning of the year. Since then, CELZ stock has decreased by 6.5% and is now trading at $4.3101. View the best growth stocks for 2024 here. When is Creative Medical Technology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our CELZ earnings forecast. How were Creative Medical Technology's earnings last quarter? Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) announced its quarterly earnings results on Friday, March, 22nd. The company reported ($1.21) earnings per share for the quarter, missing analysts' consensus estimates of ($1.13) by $0.08. When did Creative Medical Technology's stock split? Creative Medical Technology's stock reverse split before market open on Sunday, June 11th 2023. The 1-10 reverse split was announced on Sunday, June 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Creative Medical Technology's major shareholders? Creative Medical Technology's stock is owned by many different retail and institutional investors. Top institutional investors include Aaron Wealth Advisors LLC (1.21%) and Virtu Financial LLC (1.21%). Insiders that own company stock include Michael H Finger and Timothy Warbington. View institutional ownership trends. How do I buy shares of Creative Medical Technology? Shares of CELZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELZ) was last updated on 5/24/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaThis could mean the end of the U.S dollar…Colonial MetalsBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetry41 banks launch ‘crypto dollar’Stansberry ResearchBiden FINISHED On June 13th?Paradigm Press$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyA personal note from Behind The Markets' CEO Dylan Jovine...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creative Medical Technology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.